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A B S T R A C T
The present study was aimed to investigate the effects of curcumin, a representative chemopreventive phyto-
chemical with pronounced antioxidant and anti-inflammatory properties, on activation of Nrf2 and expression of
its target protein heme oxygenase-1 (HO-1) in mouse skin in vivo and in cultured murine epidermal cells.
Treatment of mouse epidermal JB6 cells with curcumin resulted in the induction of HO-1 expression, and this
was abrogated in cells transiently transfected with Nrf2 siRNA. While curcumin treatment increased protein
expression of Nrf2, it did not alter the steady-state level of the Nrf2 mRNA transcript. Treatment of cells with
curcumin stabilized Nrf2 by inhibiting ubiquitination and subsequent 26S proteasomal degradation of this
transcription factor. Tetrahydrocurcumin, a non-electrophilic analogue of curcumin that lacks the α,β-un-
saturated carbonyl group, failed to induce HO-1 expression as well as nuclear translocation of Nrf2 and its
binding to the antioxidant/electrophile response elements. Cells transfected with a mutant Keap1 protein in
which cysteine 151 (Cys151) is replaced by serine exhibited marked reduction in curcumin-induced Nrf2
transactivation. Mass spectrometric analysis revealed that curcumin binds to Keap1 Cys151, supporting that this
amino acid is a critical target for curcumin modification of Keap1, which facilitates the liberation of Nrf2. Thus,
it is likely that the α,β-unsaturated carbonyl moiety of curcumin is essential for its binding to Keap1 and sta-
bilization of Nrf2 by hampering ubiquitination and proteasomal degradation.
1. Introduction
In order to cope with a vast variety of noxious insults from the
environment, our body is endowed with efficient defense systems that
detoxify and eliminate those harmful chemicals, including carcinogens
and their reactive metabolites and also neutralize/inactivate reactive
oxygen species.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key tran-
scription factor that plays a pivotal role as a master switch that turns on
the transcription of genes encoding many carcinogen detoxifying en-
zymes as well as antioxidative and other cytoprotective proteins [1,2].
Under normal physiological conditions, Nrf2 is sequestered in the
cytoplasm through interaction with Kelch-like ECH-associated protein 1
(Keap1). Keap1 serves as an adaptor protein between Nrf2 and Cullin3-
Rbx1 E3 ligase complex, facilitating the ubiquitination and subsequent
degradation of Nrf2 by 26S proteasomes [3–5]. Under stressed condi-
tions, however, the ability of the Cullin3-Rbx1 E3 ligase to ubiquitinate
Nrf2 is repressed, which allows Nrf2 to accumulate in the nucleus,
leading to increased transcription of cytoprotective genes [2–5].
Skin is highly vulnerable to damage by environmental toxicants,
such as UV, chemical carcinogens, and infectious agents. As Nrf2-
mediated adaptive response is transient, it can be readily overwhelmed
by extensive environmental stresses. In this context, maintenance of
optimal level of defensive mechanisms is important in protecting skin
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against external insults.
Some natural products have been reported to induce activation of
Nrf2 and its target gene expression [6,7]. Curcumin, a yellow colouring
agent present in Indian spice turmeric (Curcuma longa L., Zingiber-
aceae), has strong antioxidant and anti-inflammatory activities which
account for its chemopreventive effects [8–10]. Topical application of
curcumin inhibited the chemically induced skin tumor formation in
mice [11]. Our previous study has demonstrated that topically applied
curcumin inhibited the expression of the cyclooxygenase-2 through
inhibition of NF-κB activation in mouse skin [12].
In the present study, we investigated whether curcumin could in-
duce activation of Nrf2 and cytoprotective gene expression in mouse
skin in vivo and cultured murine epidermal cells.
2. Materials and methods
2.1. Chemicals and reagents
Curcumin was purchased from LKT laboratory Inc. (St. Paul, MN,
USA). Tetrahydrocurcumin was synthesized by conventional catalytic
hydrogenation of curcumin in the presence of palladium on carbon and
generously supplied by Prof. Jeewoo Lee (College of Pharmacy, Seoul
National University). Dithiothreitol (DTT) and cycloheximide (CHX)
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine
serum (FBS), gentamycin and antibiotic–antimycotic were purchased
from Gibco BRL (Grand Island, NY, USA). Antibody against HO-1 was
obtained from stressgen (Victoria, British Columbia, Canada). Antibody
against ubiquitin was obtained from Calbiochem (Darmstadt,
Germany). All other antibodies were products of Santa Cruz
Biotechnology (Santa Cruz, CA, USA)
2.2. Cells and animals
The mouse epidermal cell line (JB6) was obtained from the
American Type Culture Collection (Manassas, VA, USA) and maintained
in Minimal Essential Medium (MEM) containing 5% FBS and 25 μg/ml
gentamycin in an atmosphere of 95% air-5% CO2 at 37 ℃. HEK293T
cells were maintained in Dulbecco’s modified Eagle’s Medium (DMEM)
with 10% FBS and antibiotic–antimycotic mixture at 37 ℃ in an at-
mosphere of 95% air-5% CO2. Female ICR mice (6–7 weeks of age) were
purchased from the Central Lab. Animal Inc. (Seoul, South Korea) and
were housed in a climate-controlled quarter (24 ± 1 °C at 50% hu-
midity) with a 12-h light/dark cycle and with free access to food and
water. Nrf2 knockout mice were kindly supplied by Dr. Jeffrey Johnson
of the University of Wisconsin-Madison. All animal experiments were
approved by the Institutional Animal Care and Use Committee (IACUC)
of Seoul National University and Keimyung University, South Korea.
2.3. Preparation and culturing mouse embryonic fibroblasts (MEFs)
MEFs were isolated from Nrf2 knockout (Nrf2−/−) and wild type
(Nrf2+/+) mice. Male and female Nrf2+/− mice were paired, and the
pregnancies were monitored. Embryos were obtained at day 13.5 after
pairing under aseptic conditions. The heads of the embryos were used
to confirm the Nrf2 genotype by PCR, and the embryo bodies were
minced into small pieces, and cultured in high glucose DMEM supple-
mented with 10% FBS and kept at 37 °C with 5% CO2.
2.4. Western blot analysis
The treated cells were harvested, washed, and suspended in the cell
lysis buffer (Cell Signaling Technology, Beverly, MA, USA). Cell lysates
were centrifuged at 13,000g for 15 min, and the aliquots of the su-
pernatant containing protein were stored at −70 ℃. Nuclear extract
from JB6 cells was prepared as described previously [13]. For in vivo
experiments, female ICR mice were treated topically on their shaven
backs with curcumin (0.1 or 1 μmol) dissolved in 200 μl of acetone and
were killed by cervical dislocation at the indicated time intervals.
Proteins from the mouse epidermis were isolated as described pre-
viously [12], and subjected to SDS-PAGE and Western blot analysis.
2.5. Immunocytochemical analysis
For the immunocytochemical analysis of Nrf2, JB6 cells were plated
on the chamber slide. After fixation with paraformaldehyde, cells were
incubated with blocking agents (0.1% Tween-20 in PBS containing 5%
bovine serum albumin), washed with PBS, and then incubated over-
night in the presence of diluted (1:100) Nrf2 primary antibody. After
washing with PBS, cells were then incubated with a FITC-conjugated
secondary antibody for 1 h. Cells were also stained with propidium
iodide (PI) and examined under a confocal microscope (Leika,
Germany).
2.6. Electrophoretic mobility shift assay (EMSA) for assessment of Nrf2-
ARE binding
A synthetic double-stranded oligonucleotide containing the Nrf2-
binding domain (ARE) was labeled with [γ-32P]ATP using a T4 poly-
nucleotide kinase and separated from the free [γ-32P]ATP by gel fil-
tration using a NICK spin column (Amersham Biosciences, UK). The
sequences of oligonucleotides in the double strands used in this study
were 5′-TTT TCT GCT GAG TCA AGG TCC G-3′ and 3′-AAA AGA CGA
CTC AGT TCC AGG C-5′. Prior to the addition of radiolabeled oligo-
nucleotide (100,000 cpm), 10 μg of the nuclear extract was kept on ice
for 15 min in gel shift binding buffer [4% glycerol, 1 mM EDTA, 1 mM
DTT, 100 mM NaCl, 10 mM Tris-HCl (pH 7.5), and 0.1 mg/ml sonicated
salmon sperm DNA]. The DNA protein complexes that formed were
resolved on a 6% nondenaturing polyacrylamide gel at 145 V for 2 h
and were subjected to autoradiography.
2.7. RNA isolation, cDNA synthesis, and reverse-transcription polymerase
chain reaction (RT-PCR)
Total RNA was isolated from cells using TRIzol® reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol. To gen-
erate the cDNA from RNA, 1 µg of total RNA was reverse transcribed
with Moloney murine leukemia virus reverse transcriptase (Promega,
Madison, WI, USA) for 50 min at 42 °C and again for 15 min at 72 °C.
One μl of cDNA was amplified in sequential reactions using Maxime
PCR PreMix Kit (iNtRON Biotechnology, Seoul, South Korea). For
quantitation of HO-1 mRNA, 20 cycles of 94 °C for 30 s, 53 °C for 35 s,
and 72 °C for 30 s; for quantification of Actin mRNA, 20 cycle of 94 °C
for 30 s, 59 °C for 35 s, and 72 °C for 30 s; for quantitation of Nrf2
mRNA 20 cycle of 94 °C for 30 s, 59 °C for 35 s, and 72 °C for 30 s were
conducted. These PCR cycles were followed by a final extension for
5 min at 72 °C. The primers used for each RT-PCR reactions are as
follows: HO-1, 5′-TAC ACA TCC AAG CCG AGA AT-3′ and 5′-GTT CCT
CTG TCA GCA TCA CC-3′; Nrf2, 5′-TCT CCT CGC TGG AAA AAG AA-3′
and 5′-AAT GTG CTG GCT GTG CTT TA-3′; Actin, 5′-AGA GCA TAG CCC
TCG TAG AT-3′ and 5′-CCC AGA GCA AGA GAG GTA TC-3′ (forward
and reverse, respectively). Amplification products were analyzed by
2.0% agarose gel electrophoresis, followed by staining with ethidium
bromide, and then photographed under ultraviolet light.
2.8. Plasmids and transient transfection
Construction of plasmids pcDNA3-Myc3-Nrf2 (Addgene plasmid
21555) and pcDNA3-HA2-Rbx1/ROC1 (Addgene plasmid 19897) was
described elsewhere [13,14]. The full-length human cDNA of Keap1was
obtained from Thermo Fisher Scientific (Huntsville, AL, USA) and
subcloned into pCMV-FLAG-MAT™-1 expression vector (Sigma-Aldrich,
St. Louis, MO, USA) as HindIII/BamHI fragment. The full-length human
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Cullin3 was amplified by RT-PCR of the total RNA obtained from
HEK293T cells with primers 5′-TAA GGT ACC AAT GTC GAA TCT GAG
CAA-3′ (forward) and 5′-GCC TCG AGT TAT GCT ACA TAT GTG TAT
AC-3′(reverse) and subcloned into His-tagged pcDNA6 expression
vector (Invitrogen, Carlsbad, CA, USA) as KpnI/ApaI fragment. The
reporter gene fusion constructs for wild type ARE were kindly provided
by Prof. Jeffrey A. Johnson (University of Wisconsin-Madison). For
plasmid transfection, cells were seeded and grown to 40–50% con-
fluence growth media without antibiotics. Each plasmid was transfected
into cells with lipofectamine LTX and PLUS reagent according to the
instructions supplied by the manufacturer (Invitrogen, Carlsbad, CA,
USA). For siRNA transfection, cells were transfected with Nrf2 siRNA
(Invitrogen, Carlsbad, CA, USA) by lipofectamine RNAi-MAX reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s in-
structions.
2.9. Luciferase reporter gene assay
JB6 cells were grown up to 50% confluence in 12-well plates in
complete media that do not contain antibiotics. Then, the cells were
transfected with 100 ng of ARE-Luc vector (pGL2-NQO1) by using the
Lipofectamine LTX according to the instructions supplied by the man-
ufacturer (Invitrogen, Carlsbad, CA, USA). In all cases, the total amount
of transfecting plasmid DNA was quantitated and adjusted using
pcDNA3-β-galactosidase. After the following 24-h transfection, cells
were treated for additional 6 h with 5 μM each of curcumin or tetra-
hydrocurcumin, and the lysis of transfected cells was carried out using
the reporter lysis buffer. After mixing the cell extract with a luciferase
substrate (Promega, Madison, WI, USA), the luciferase activity was
measured by employing a luminometer (AntoLumat LB953, EG&G
Berthold, Bad Widbad, Germany). The β-galactosidase assay was done
according to the supplier’s instructions (Promega β-galactosidase
Enzyme Assay System) for normalizing the luciferase activity. For de-
termining the effect of cysteine 151 (Cys151) mutation of Keap1 on
Fig. 1. Effects of curcumin on the activation of Nrf2
and expression of its target protein, HO-1 in mouse
skin in vivo. Dorsal skin of female ICR mice was
treated topically with 1 μmol of curcumin for in-
dicated time periods. (A, B) After treatment, the
protein levels of Nrf2 (A) and HO-1 (B) in the epi-
dermal tissue lysates were measured by Western blot
analysis as described in Materials and methods. (C)
The expression of Nrf2 and HO-1 was measured
under the same experimental conditions by Western
blot analysis after 12-h topical curcumin treatment.
The protein expression levels of Nrf2 and HO-1 were
quantified using an image analysis software GelPro
3.1 and normalized to the vehicle (DMSO) control. A
bar graph represents the mean of triplicates ± SD.
(D) Mice were treated with 1 μmol curcumin and
killed at the indicated times. The nuclear fraction was
isolated as described in Materials and methods. The
Nrf2-ARE binding activity was assessed by EMSA.
Nuclear extracts were incubated with [γ-32P]-labeled
oligonucleotides harboring the ARE consensus se-
quence, and the Nrf2-ARE oligonucleotide complex
was resolved by gel electrophoresis.
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Nrf2 transcriptional activity, HEK293T cells were transfected for 24 h
with pGL2-NQO1 vector, expression plasmids for wild type Myc-Nrf2
and Flag-Keap1 or mutant Keap1. Transfected cells were treated with or
without curcumin (15 μM) before the reporter assay.
2.10. Immunoprecipitation
Cells were treated with curcumin for indicated time and cells were
lysed in 250 mM sucrose, 50 mM Tris-HCl (pH 8.0), 25 mM KCl, 5 mM
MgCl2, 1 mM EDTA, 2 μM NaF, 2 μM sodium orthovanadate and 1 mM
phenylmethylsulfonyl fluoride. Total protein (500 μg) was subjected to
immunoprecipitation by shaking with Nrf2 primary antibody at 4℃ for
2 h followed by the addition of protein G-agarose bead suspension (25%
slurry, 40 μl) and additional shaking for 2 h at 4 ℃. In another ex-
periment, HEK 293 T cells were lysed in buffer described previously
[15], and 400 μg of cellular proteins were subjected to
Fig. 2. Curcumin-induced expression of Nrf2 and HO-1 in JB6 cells. (A) JB6 cells were treated for the indicated time periods with 5 μM curcumin. The total protein
was isolated and analyzed for the measurement of Nrf2 protein by Western blot analysis. (B) JB6 cells were treated with 5 µM curcumin and harvested at indicated
time points. The nuclear fraction was isolated as described in Materials and methods, and Nrf2 levels were assessed by Western blot analysis. (C) JB6 cells were
treated with 5 μM curcumin for the indicated time, and total mRNA were isolated and analyzed for the expression levels of Nrf2 mRNA transcript by RT-PCR. (D)
After treatment with curcumin (5 μM) for indicated time periods, RT-PCR analysis was performed to measure mRNA expression of HO-1 as described in Materials and
methods.(E) JB6 cells were treated for indicated time points with 5 μM curcumin. Total proteins were isolated and subjected to the Western blot analysis for the
measurement of HO-1 protein expression. (F) The expression of Nrf2 and HO-1 was measured by Western blot analysis after 6-h curcumin treatment. Band intensities
were quantified and normalized to the vehicle (DMSO) control. Data are means ± SD (n = 3).
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immunoprecipitation by shaking with an indicated antibody at 4 ℃ for
2 h followed by shaking with protein G-agarose suspension (25% slurry,
40 μl) at same condition. After centrifugation at 3000 rpm for 30 s,
immunoprecipitated beads were collected by discarding the super-
natant and washed with cell lysis buffer. After final wash, im-
munoprecipitate was resuspended in 40 μl of 1X SDS electrophoresis
sample buffer and boiled for 3 min. Ten μl of supernatant from each
sample was loaded on SDS-polyacrylamide gel.
2.11. Covalent docking simulation of interaction between curcumin and
Keap1
Covalent docking simulation was performed to predict binding pose
of curcumin with selected reactive cysteine residues of mouse Keap1
protein using CovDock module implemented in Schrödinger program
(Schrödinger, L.L.C., New York, NY, USA). In our previous study [16], a
homology model of mouse Keap1 structure based on human Keap1 BTB
domain (PDB ID: 4CXI) and human KLKL11 BTB and BACK domains
(PDB ID: 3I3N) was used for covalent docking simulation. The same
approach was adopted to predict the interaction between curcumin and
Keap1 selected cysteine residues. Preparation of the protein structure
was processed through “Protein Preparation Wizard” in Schrodinger
program. The minimization was terminated when the root mean square
deviation of the heavy atoms in the energy minimized structure relative
to the starting coordinates exceeded 0.3 Angstrom using OPLS3e force
field. The grid size for covalent docking simulation was set to 15 Å of
the centroid of cysteine residue in position of 151, 273 and 288 amino
acids. Curcumin was sketched and was minimized with MMFFs force
field through “LigPrep” in Schrodinger program. Flexible ligand sam-
pling with SP docking mode was considered in the docking procedure.
The predefined “Michael Addition” reaction was used to form covalent
bonds. All other parameters were set to defaults for the CovDock
docking procedure.
2.12. Detection of modified Keap1
Recombinant human Keap1 (0.06 μM, Abnova, Taipei, Taiwan) was
incubated with 0.6 μM of curcumin in 100 μl of recombinant protein
storage buffer (50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0)
for 2 h at room temperature. The reaction was quenched by adding
60 μM of DTT, and the mixture was incubated for another 15 min.
Proteins were separated by NuPAGE® 4–12% Bis-Tris Gel (Invitrogen,
Carlsbad, CA, USA). For the identification of curcumin-modified Keap1,
gels were treated with endoproteinase Chymotrypsin (Roche,
Mannheim, Germany) at 25 ℃ overnight. Following digestion, proteo-
lytic peptides were extracted and dried with SpeedVac. Resuspended
samples in 0.1% formic acid were purified and concentrated using C18
ZipTips (Millipore, Burlington, MA, USA) before MS analysis. The
proteolytic peptides were loaded onto a fused silica microcapillary
column (12 cm × 75 µm) packed with C18 reversed-phase resin (5 µm,
200 Å). Peptide separation was conducted in a series of step gradients
composed of initial isobaric flow for 5 min with 3% solvent B (0.1%
formic acid in acetonitrile), then linear gradient from 3% to 35% for
30 min, followed by linear gradient to 40% for 5 min. At the end of each
running, 90% of solvent B was eluted for 10 min with a rate of 250 nl/
min. The % gradient of solvent B was against solvent A (0.1% formic
acid in H2O). The column was directly connected to LTQ linear ion-trap
mass spectrometer (Finnigan, CA, USA) equipped with a nano-electro-
spray ion source. Each full MS scan was followed by five MS/MS scan
from the most intense to the fifth intense peaks of full MS scan. The
acquired LC-ESI-MS/MS fragment spectra were searched in the
BioWorksBrowserTM (version Rev. 3.3.1 SP1, Thermo Fisher Scientific
Inc., CA, USA) with the SEQUEST search engines against the data in
FASTA format generated from Keap1, transcript variant 1, mRNA (NCBI
Fig. 3. Role of Nrf2 in curcumin-induced HO-1
expression in mouse epidermal cells. (A) JB6
cells were transfected transiently with siRNA-
Nrf2 and treated with 5 μM curcumin for 6 h.
Protein was isolated and analyzed for the mea-
surement of HO-1 protein by Western blot ana-
lysis. (B) MEFs isolated from Nrf2 wild type or
knock out mice were treated for 12 h with 20 μM
of curcumin. After treatment, the cells were
harvested, lysed and subjected to Western blot
analysis to determine the levels of Nrf2 and HO-
1. Data are means ± SD (n = 3).
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accession number NM_203500) in National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov). The conditions for the
search were as follows; Chymotrypsin as enzyme specificity, a permis-
sible level for two missed cleavages, peptide tolerance;± 2 amu, a mass
error of± 1 amu on fragment ions and variable modification of cy-
steine (+57 Da), oxidation of methionine (+16 Da) and curcumin
modification of cysteine (+372.14 Da) residues.
3. Results
3.1. Topically applied curcumin induces expression of Nrf2 and HO-1 in
mouse skin
Topical application of 1 μmol curcumin onto the back of mouse
induced the expression of Nrf2 (Fig. 1A) and its target cytoprotective
protein, HO-1 (Fig. 1B) in a time-dependent manner. In another ex-
periment, topically applied curcumin (0.1 and 1 μmol) for 12 h upre-
gulated expression of Nrf2 and HO-1 in a dose-dependent manner
(Fig. 1C). Nrf2, once translocated into the nucleus, binds to ARE present
in the promoter regions of target genes. Topically applied curcumin
induced transient increase in the binding of Nrf2 to the oligonucleotide
harbouring the ARE consensus sequence (Fig. 1D).
3.2. Curcumin induces transcription and translation of HO-1 through Nrf2
activation in mouse epidermal cells
Like that observed in mouse skin, the treatment of mouse epidermal
JB6 cells with curcumin (5 μM) induced the expression of Nrf2 protein
in a time-dependent manner (Fig. 2A), predominantly in the nucleus
(Fig. 2B). However, the steady-state levels of Nrf2 mRNA remained
unchanged (Fig. 2C). In another experiment, curcumin treatment in-
creased the expression of HO-1 at both transcriptional (Fig. 2D) and
translational (Fig. 2E) levels in JB6 cells in a time-dependent manner.
The curcumin-induced expression of Nrf2 and HO-1 was concentration-
dependent as well (Fig. 2F). To determine whether curcumin-induced
HO-1 expression is mediated by Nrf2, JB6 cells were transiently
transfected with Nrf2 siRNA or control siRNA, and the expression of
both Nrf2 and HO-1 was compared by Western blot analysis. Results
shown in Fig. 3A demonstrates that siRNA knockdown of Nrf2 gene
abrogated the expression of HO-1. Similarly, embryo fibroblasts from
Nrf2 deficient mice were not responsive to curcumin-induced en-
hancement of HO-1 expression (Fig. 3B). This finding indicates that
Nrf2 is essential for the curcumin-induced up-regulation of HO-1 ex-
pression in mouse epidermal cells.
3.3. Curcumin stabilizes Nrf2 by blocking ubiquitin-dependent 26S
proteasomal degradation
As illustrated in Fig. 2A and B, curcumin induced protein expression
of Nrf2 without altering the steady-state level of its mRNA transcript
(Fig. 2C). This prompted us to suggest protein stabilization as a plau-
sible mechanism underlying Nrf2 activation by curcumin. To test this
supposition, we monitored the degradation of basal and curcumin-in-
duced Nrf2 protein in JB6 cells after blockade of de novo protein
synthesis by CHX. Residual Nrf2 protein existing in the untreated cells
underwent rapid degradation after the addition of CHX. Nrf2 in cur-
cumin-treated JB6 cells, however, was more stable than that of un-
treated cells (Fig. 4A). Like the majority of other regulatory proteins,
Nrf2, is mainly degraded by the 26S proteasomes. Nrf2 is covalently
modified by ubiquitin molecules, a highly conserved ~8 kDa poly-
peptide, at the ε-amino group of Nrf2 lysine residues before degraded
by the 26S proteasomes. As shown in Fig. 4B, ubiquitination of Nrf2
was decreased in cells treated with curcumin.
3.4. The α,β-unsaturated carbonyl group of curcumin is essential for its
activation of Nrf2 and subsequent HO-1 expression
It is well known that Keap1 plays an essential role in Cullin3-Rbx1
E3 ligase as a sensor of oxidative and electrophilic stresses. Keap1
contains several highly conserved cysteine residues that are molecular
targets of chemopreventive agents for the activation of Nrf2. As cur-
cumin has an electrophilic α,β-unsaturated carbonyl moiety (Fig. 5A), it
may covalently modify one or more of these cysteine residues present in
Keap1. As an initial approach to explore this possibility, JB6 cells were
co-incubated with curcumin and DTT, a thiol reducing agent that can
modify cysteine residues. DTT treatment attenuated curcumin-induced
expression of Nrf2 and HO-1 in JB6 cells (data not shown). In addition,
tetrahydrocurcumin, which lacks the α,β-unsaturated carbonyl moiety
(Fig. 5A), failed to induce the nuclear accumulation of Nrf2 as assessed
by Western blot (Fig. 5B) and immunocytochemical (Fig. 5C) analyses.
Likewise, tetrahydrocurcumin was unable to promote ARE-driven
transcriptional activity of Nrf2 (Fig. 5D) and its target protein expres-
sion (Fig. 5E).
Fig. 4. Curcumin-induced stabilization of Nrf2 protein. (A) JB6 cells were
treated with 5 μM of curcumin for 6 h and then challenged with 0.1 mg/ml CHX
for the indicated time periods. Nrf2 was detected by Western blot analysis. (B)
After treatment of JB6 cells with 5 μM of curcumin for 6 h, 500 μg of each
protein sample was immunoprecipitated with anti-Nrf2 antibody and visualized
by Western blot analysis with anti-ubiquitin antibody.
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3.5. Modification of the cysteine 151 residue in Keap1 by curcumin is
important for its stimulation of Nrf2 transcriptional activity
Among the cysteine residues present in murine Keap1, Cys151,
Cys273 and Cys288 are of particular importance to regulate Nrf2 ac-
tivity. Prediction of covalent docking pose of curcumin was performed
with these reactive cysteine residues in a mouse Keap1 homology model
[16]. According to this docking model, Cys151 is located at the tip of
the flexible loop in the BTB domain, while Cys273 and Cys288 reside in
the intervening region of the IVR domain (Fig. 6A). Molecular docking
simulation represents that the α,β-unsaturated carbonyl group of cur-
cumin covalently binds to the reactive sulfur atom of Keap1 cysteine
residues by Michael addition (Fig. 6B–D). Two carbonyl groups and the
phenolic hydroxyl group of curcumin adducted to Cys151 residue form
hydrogen bonds with the ε-amino group of Lys131 and the carboxyl
group of Pro89 residues, respectively and the other phenyl moiety in-
teracts with the His154 residue through π-π stacking interaction
(Fig. 6B). Curcumin shows unfavorable binding pose to the Cys273
residue (Fig. 6C) while it has a stable interaction with Cys288 via two
hydrogen bonds between its two phenolic hydroxyl groups and Ser243
and Glu289 residues (Fig. 6D). Cdock affinity of curcumin to Cys151,
Cys273 and Cys288 was −3.31, −2.37 and −3.41 kcal/mol, respec-
tively.
We further conducted LC-ESI-MS/MS analysis to identify the
binding site(s) of curcumin. Human recombinant Keap1 incubated with
curcumin was digested with chymotrypsin, and analyzed by tandem
mass spectrometry. An increment of molecular mass by curcumin
modification was observed in the peptide fragments (y5+ and [b10-
H2O]+) containing Cys151 (Fig. 7A).
Accordingly, the effects of curcumin on Nrf2 transcriptional activity
were examined in the cells transfected with wild type or cysteine mu-
tant Keap1 together with Nrf2. As shown in Fig. 7B, curcumin treatment
enhanced Nrf2 activity in the cells transfected with Nrf2 and wild type
Keap1, but not in those cells harbouring Cys151 mutant Keap1. These
findings suggest that curcumin interacts with Cys151 residue in Keap1,
thereby hampering Keap1-mediated Nrf2 suppression.
Fig. 5. Comparative effects of curcumin and
tetrahydrocurcumin on nuclear translocation
and transcriptional activity of Nrf2 in JB6 cells.
(A) Chemical structures of curcumin and tetra-
hydrocurcumin. Curcumin has an α,β-un-
saturated carbon which is considered to target
nucleophiles whereas tetrahydrocurcumin has
no such electrophilic moiety. (B) JB6 cells were
treated with 2.5 or 5 μM of curcumin or its non-
electrophilic analog tetrahydrocurcumin.
Nuclear protein was isolated and analyzed for
the measurement of Nrf2 expression by Western
blot analysis, and band intensities were quanti-
fied. Data are means ± SD (n = 3). (C) JB6
cells (1 × 104 per well) were seeded onto 4-
chamber coverglasses immersed in 500 μl of 5%
FBS-MEM. After 24 h incubation, cells were
treated with curcumin or tetrahydrocurcumin at
5 μM concentration each for 6 h, and im-
munocytochemical analysis of Nrf2 was con-
ducted. (D) JB6 cells were transfected tran-
siently with 100 ng of pGL2-NQO1, and 24 h
later, the cells were treated with 5 μM each of
curcumin or tetrahydrocurcumin for additional
6 h. Cell lysates were then assayed for the luci-
ferase activity. (E) JB6 cells were treated with
2.5 or 5 μM of curcumin or its non-electrophilic
analog tetrahydrocurcumin. Total proteins were
isolated and subjected to the Western blot ana-
lysis for the measurement of HO-1 protein ex-
pression and band intensities were quantified.
Data are means ± SD (n = 3).
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3.6. Curcumin increases interaction between Nrf2 and Keap1 without
altering the association between the components of Cullin3-Rbx1 E3 ligase
complex
Under normal physiological conditions, Keap1 sequesters Nrf2 in
the cytoplasm targeting it for ubiquitination and proteasomal de-
gradation. To determine whether increased accumulation of Nrf2 by
curcumin results from decreased interaction between Nrf2 and Keap1,
the levels of Keap1-associated Nrf2 were determined after curcumin
treatment. When HEK293T cells were transfected with expression
vectors for Nrf2 and Keap1 followed by immunoprecipitation with
Keap1 antibody, an increase in Keap1-associated Nrf2 was observed
(Fig. 8A). It is known that disruption of binding between Keap1 and
Cullin3 results in decreased activity of Cullin3-Rbx1 E3 ubiquitin ligase.
This prompted us to examine the effects of curcumin on Cullin3-Rbx1
E3 ligase complex assembly. Curcumin treatment, however, didn’t alter
the interaction between Cullin3-Keap1 (Fig. 8B) and Cullin3-Rbx1
(Fig. 8C). These results suggest that curcumin increases Nrf2 stability by
repressing the ability of Keap1 to efficiently target Nrf2 for ubiquitin-
mediated degradation rather than release Nrf2 from Keap1.
4. Discussion
Nrf2, as a master switch in turning on transcription of many carci-
nogen detoxifying and antioxidant genes, is considered a prime target
for chemoprevention by a wide spectrum of edible phytochemicals
[6,7]. Under basal conditions, Keap1 binding to Cullin3 enables the
complex to degrade Nrf2 through ubiquitination and subsequent 26S
proteasomal degradation [2–5]. Some electrophiles bind to Keap1 and
disrupt proteasome-mediated degradation of Nrf2. For instance, the
adduction of Keap1 cysteine(s) by such electrophilic substances as
sulforaphane and tert-butyl hydroquinone changes the conformation of
Fig. 6. Covalent docking pose of curcumin in BTB and IVR domains of mouse Keap1 protein. (A) A model of Keap1 BTB and IVR structures with three cysteine
residues in position of 151, 273 and 288. The covalent binding pose of the α,β-unsaturated carbonyl group of curcumin to Cys151 (B), Cys273 (C) and Cys288 (D)
residues is shown. Gray carbon-capped sticks are the amino acids of Keap1. Green dashed lines are hydrogen bonds.
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ligase and promotes the escape of Nrf2 from proteasomal degradation
[17–19]. Curcumin bears two electrophilic α,β-unsaturated carbonyl
moieties. Therefore, modification of Keap1 cysteine(s) by this electro-
philic phytochemical through Michael addition reaction is speculated to
provoke conformational changes in Keap1, impairing its ability to
suppress Nrf2 activation.
Several different mechanisms appear to be involved in Nrf2 acti-
vation by Keap1 cysteine modifications. It is noticeable that Keap1 is
not merely a repressor that sequesters Nrf2 in the cytoplasm, but rather
acts as an active mediator that targets Nrf2 for ubiquitination and
proteasomal degradation. Keap1 functions as a substrate adaptor pro-
tein for the Cullin3-Rbx1 E3 ubiquitin ligase complex (3–5). Keap1
protein contains several cysteine(s), which are highly conserved across
species. Among these, Cys151, Cys273, and Cys288 are considered as
sensors for electrophiles and oxidants that are capable of inducing the
transcriptional activity of Nrf2 [17]. In particular, mutation of Cys151
to serine has been shown to abolish electrophile- and oxidant-mediated
Nrf2 ubiquitination [20]. In line with this observation, our results in-
dicate that Cys151 is required for transcriptional activity of Nrf2 in
response to curcumin treatment. The other two cysteine residues,
Cys273 and Cys288 are required for Keap1 to repress Nrf2-dependent
transcriptional activation [17]. However, curcumin-induced Nrf2
transcriptional activity was barely impaired in cells harbouring mutant
Keap1-C273S and Keap1-C288S (data not shown). Based on these
findings, we speculate that Cys151 may be a putative binding site of
curcumin. Mass spectral analysis revealed that Keap1 Cys151 was
modified by curcumin, corroborating the above speculation.
According to the current paradigm, electrophilic adduction of Keap1
Cys151 may dissociate Keap1 from Cullin3 and decrease the activity of
Cullin3-Rbx1 E3 ubiquitin ligase. An early independent study suggested
that modification of Keap1 cysteine(s) by ARE inducers directly disrupts
the interaction between Keap1 and Nrf2 [21]. However, subsequent
experiments demonstrated that the disruption of the Keap1-Nrf2 com-
plex did not occur upon modification of Keap1 cysteine [22,23]. While
Fig. 7. Cysteine 151 of Keap1 as a putative
binding site of curcumin for its activation of
Nrf2. (A) Human recombinant Keap1 (5.64 μg)
was incubated for 1 h at room temperature in
final volume of 100 μl containing 600 nM cur-
cumin, followed by adding 60 μM DTT for
15 min. Proteolytic Keap1 peptides were ana-
lyzed by mass spectrometry. (B) HEK293T cells
were transfected with plasmids containing an
ARE-driven luciferase reporter gene, expression
plasmids for wild type Myc-Nrf2 and Flag-Keap1
or mutant Keap1. Transfected cells were treated
with vehicle or curcumin (15 μM) for 6 h before
the reporter assay as described in Materials and
methods. Data are means± SD (n = 3).
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modification of Keap1 cysteine does not alter the affinity of Keap1 for
Nrf2, recent data indicate that the Keap1-Cullin3 interaction is altered
by Keap1 cysteine modification [23,24]. These results suggest that the
reaction of ARE inducers with Keap1 cysteine leads to reduced asso-
ciation between Keap1 and Cullin3, thereby repressing Nrf2 ubiquiti-
nation. This would, in turn, lead to Nrf2 accumulation.
Although the Cullin3-Keap1 interaction among the components of
Cullin3-Rbx1 E3 ligase complex is an important aspect of its ability to
ubiquitinate Nrf2, this cannot fully account for the mechanisms reg-
ulating the activation of Nrf2 signaling. Cope and Deshaies proposed an
interesting model that Cullin-dependent ubiquitin ligase is a very dy-
namic structure regulated by cycles of assembly and disassembly for
efficient degradation of target proteins [25]. The main point of this
model is that the Cullin-Rbx1 core complex cycles between active and
inactive states. In addition, several studies suggest that cyclical as-
sembly and disassembly of Cullin dependent E3 ligase complex is par-
tially mediated by the antagonistic action of Nedd8 modification of the
Cullin protein and association of Cullin protein with Cullin-associated
NEDD8-dissociated protein 1 (CAND1) [26–28]. In the active state, the
Cullin protein is modified by Nedd8 conjugation, and the conjugated
Nedd8 polypeptide may also promote the ubiquitination of targets and
prevent binding of the inhibitor CAND1 [29,30]. Thus it is possible that
modification of Keap1 Cys151 by curcumin causes a conformational
change of Cullin3 to enhance deneddylation states of Cullin3 or inter-
action between CAND1 and Cullin3, leading to the reduced activity of
Cullin3-Rbx1 E3 ubiquitin ligase. However, further experiments are
required to elucidate precise molecular mechanisms responsible for the
regulation of Cullin3 activity by curcumin.
While covalent modification of Keap1 cysteine thiol appears to be a
principal mechanism by which curcumin stabilizes Nrf2, other reg-
ulatory mechanisms are also involved in Nrf2 activation. Some studies
demonstrated that phosphorylation of Nrf2 also appears to play an
important role in activating Nrf2 by ARE inducers. The activity of
protein kinase C (PKC) was stimulated by various ARE inducers, and the
sole site of phosphorylation by PKC was identified as Ser40 [31–33].
The result from co-IP experiments demonstrated that phosphorylation
of Nrf2 by PKC in vitro promotes its dissociation from Keap1, and this
effect was largely hampered by S40A mutation [32]. In addition, p38
mitogen-activated protein kinase (MAPK) isoforms have been im-
plicated in Nrf2 signaling, and alteration of the Keap1-Nrf2 affinity has
Fig. 8. Effects of curcumin on interaction between Nrf2 and Keap1, Keap1 and Cullin3 and Cullian3 and Rbx1. (A, B and C) HEK293T cells were transfected with
plasmids of 500 ng Myc-Nrf2 (A), 1,000 ng Flag-Keap1 (B), 1,000 ng Xpress-Cullin3 (B,C), 1,000 ng HA-Rbx1 (C) and 1,000 ng T7-Keap1 (A) for 24 h as indicated,
followed by treatment with curcumin (15 μM) for the indicated time. Cell lysates were subjected to immunoprecipitated and immunoblotting using antibodies against
Keap1, Cullin3, HA, Myc and T7.
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been proposed as the mechanistic explanation [34]. Specific inhibitors
of p38 MAPK, PKC and phosphatidylinositol 3-kinase have been re-
ported to attenuate curcumin-induced Nrf2 activation [35–37].
In conclusion, our study revealed that curcumin inhibits the ability
of the Cullin3-Rbx1 E3 ubiquitin ligase complex to target Nrf2 for
ubiquitination by modifying Keap1 Cys151 residue. This modification
may change the conformation of the complex and saturates the binding
capacity of Keap1 to Nrf2, facilitating nuclear translocation of de novo
synthesized Nrf2 (Fig. 9).
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